Trevi Therapeutics, Inc. (“Trevi”), a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus, presented data on nalbuphine at the 7th World Congress on Itch.
Nalbuphine is a mixed mu antagonist/kappa agonist opioid. The effect of nalbuphine on substance P induced scratching was studied by Trevi in the mouse model. This model is relevant to antihistamine-resistant pruritus, which is observed in patients with various dermatopathologies.
Help employers find you! Check out all the jobs and post your resume.
